Tumor antigens presented by autologous myeloid dendritic cells (DC-TAA)

Tumor antigens presented by autologous myeloid dendritic cells (DCs) represent a therapeutic approach in cancer immunotherapy where a patient's own dendritic cells are harvested, matured, and loaded with tumor-specific or tumor-associated antigens (TAAs) (Wculek et al., 2020, Nature Reviews Immunology). These antigens can be derived from tumor lysates, synthetic peptides, or nucleic acids encoding specific proteins (NCI Drug Dictionary). Once re-infused into the patient, these myeloid DCs act as professional antigen-presenting cells (APCs), displaying the antigens via Major Histocompatibility Complex (MHC) molecules to naive and memory T-cells (Banchereau & Palucka, 2005, Nature Reviews Cancer). This interaction, supported by co-stimulatory signals, triggers a robust, tumor-specific cytotoxic T-lymphocyte (CTL) response aimed at eradicating malignant cells. This modality is primarily utilized in the treatment of various solid tumors and hematologic malignancies, aiming to overcome the immunosuppressive environment of the tumor and establish long-term immunological memory (Santos & Butterfield, 2018, Journal of Immunology).

Other names

Dendritic cell vaccineDC-based immunotherapyAutologous DC-presented antigensAntigen-loaded myeloid dendritic cellsDC-presented tumor-associated antigens

Induction of tumor-specific T-cell immunity through the presentation of tumor-associated antigens on MHC molecules by autologous dendritic cells.